LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

LLY

1,144.58

+1.28%↑

JNJ

232.3

-0.15%↓

ABBV

222.66

-2.06%↓

UNH

405.72

+1.35%↑

MRK

119.23

-1.41%↓

Kodu・Aktsiate loetelu・Lantheus Holdings Inc

Lantheus Holdings Inc

Suletud

SektorTervishoid

100.07 -0.49

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

99.65

Max

102.26

Põhinäitajad
By Trading Economics
Sissetulek	64M 118M
Müük	-29M 377M
P/E Sektori keskmine	23.181 49.888
Aktsiakasum	1.46
Kasumimarginaal	31.383
Töötajad	1,193
EBITDA	-17M 81M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+4.97% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. aug 2026

Turustatistika
By TradingEconomics
Turukapital	609M 6.3B
Eelmine avamishind	100.56
Eelmine sulgemishind	100.07

Uudiste sentiment

By Acuity

16%

84%

28 / 344 Pingereas Healthcare

Lantheus Holdings Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. juuni 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8. juuni 2026, 15:41 UTC

Suurimad hinnamuutused turgudel

American Battery Shares Jump on Energy Department Victory

8. juuni 2026, 23:46 UTC

Market Talk

Nikkei May Rebound After Monday's Selloff -- Market Talk

8. juuni 2026, 23:37 UTC

Market Talk

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8. juuni 2026, 23:25 UTC

Market Talk

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8. juuni 2026, 23:25 UTC

Market Talk

Global Equities Roundup: Market Talk

8. juuni 2026, 21:57 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8. juuni 2026, 21:56 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Agrees to Buy m3ter

8. juuni 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

8. juuni 2026, 19:22 UTC

Market Talk

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8. juuni 2026, 19:01 UTC

Market Talk

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8. juuni 2026, 18:52 UTC

Market Talk

Global Energy Roundup: Market Talk

8. juuni 2026, 18:52 UTC

Market Talk

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8. juuni 2026, 18:17 UTC

Market Talk

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8. juuni 2026, 17:32 UTC

Market Talk

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8. juuni 2026, 17:29 UTC

Market Talk

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8. juuni 2026, 17:29 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. juuni 2026, 16:55 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8. juuni 2026, 16:54 UTC

Omandamised, ülevõtmised, äriostud

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8. juuni 2026, 16:40 UTC

Market Talk

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8. juuni 2026, 16:31 UTC

Market Talk

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8. juuni 2026, 16:27 UTC

Market Talk

Mexican Inflation Seen Easing in May -- Market Talk

8. juuni 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. juuni 2026, 16:03 UTC

Omandamised, ülevõtmised, äriostud

Orange Bought Stake From Lorca

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8. juuni 2026, 16:01 UTC

Omandamised, ülevõtmised, äriostud

Orange Acquires 100% Ownership of MasOrange

8. juuni 2026, 15:58 UTC

Market Talk

Global Equities Roundup: Market Talk

8. juuni 2026, 15:58 UTC

Market Talk

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8. juuni 2026, 15:55 UTC

Market Talk

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8. juuni 2026, 15:41 UTC

Market Talk

Gold Falls Below 200-Day Moving Average -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Lantheus Holdings Inc Prognoos

Hinnasiht

By TipRanks

4.97% tõus

12 kuu keskmine prognoos

Keskmine 106 USD 4.97%

Kõrge 115 USD

Madal 94 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Lantheus Holdings Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Lantheus Holdings Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

28 / 344 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lantheus Holdings Inc

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.